Skip to main content
. 2018 Nov 28;54(2):431–442. doi: 10.3892/ijo.2018.4650

Figure 4.

Figure 4

TM enhances the suppressive effects of cisplatin in lung cancer cells. (A) CCK-8 assay was used to examine the viability of A549 and SPCA1 cells treated with TM, Cis or in combination for 0-72 h. Data were expressed as a percentage of viable cells. (B) Representative images of A549 and SPCA1 cell colonies following treatment with TM, Cis. (C) Images representation of wound healing of A549 and SPCA1 cells analyzed following treatment with TM or Cis alone or in combination, graphs were the measurement of relative wound width (48 h average wound width divided by 0 h wound width). (D) Images and graphs of transwell assay of A549 and SPCA1 cells following treatment with TM, Cis alone or in combination. (E) Invasion ability of A549 and SPCA1 cells following treatment with TM, Cis alone or in combination for 15 h. Bar graph values represented the number of invaded cells from ten different field. (F) Western blot analysis of PCNA and MMP-9 expression following treatment with TM, Cis alone or in combination. GAPDH was used as an internal control. Data was shown as the mean values ± SEM. *P<0.05 and **P<0.01.